Integrative analysis of RNA expression signatures and recurrent genomic alterations before treatment: link to menopausal status, short-term endocrine therapy response and disease-free survival in luminal breast cancer.

ABSTRACT:

Background

Endocrine therapy with tamoxifen (TAM) or aromatase inhibitors (AI) is an effective treatment of patients with estrogen receptor-positive, HER2-negative luminal breast cancer. However, many patients do not respond to this therapy, leading to disease recurrence. This study aimed to identify baseline clinical, molecular, and genetic features associated with menopause status, primary endocrine therapy resistance and long-term outcomes in luminal breast cancer.

Patients and methods

We analyzed 220 patients from the WSG-ADAPT trial with early-stage, estrogen receptor-positive, HER2-negative breast cancer, who received 3 weeks of preoperative endocrine therapy with TAM or AI. Tumor samples obtained before treatment were profiled using the NanoString BC360 panel, and sam

SUBMITTER: Zhang G 

PROVIDER: S-EPMC12681821 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature